


Patent No.: 6,335,031  
Application No.: 09/291,498  
For: TTS CONTAINING AN ANTIOXIDANT


**PATENT OWNER'S POWER OF ATTORNEY IN AN INTER PARTES REVIEW**





Patent Owner Novartis AG ("Novartis") hereby appoints Raymond R. Mandra (Reg. No. 34,382) and Nicholas N. Kallas (Reg. No. 31,530) as its attorneys to prosecute the aforementioned proceeding and to transact all business in the United Patent and Trademark Office connected therewith.





Please address all correspondence as follows:

Raymond R. Mandra  
Fitzpatrick, Cella, Harper & Scinto  
1290 Avenue of the Americas  
New York, NY 10104-3800  
Telephone: (212) 218-2100  
Facimile: (212) 218-2200  
rmandra@fchs.com

Dated: November 25, 2014  
  
Andrea Jacquin  
Novartis Pharmaceuticals Corporation  
One Health Plaza  
East Hanover, NJ 07936-1080

Dated: November 25, 2014  
  
Gregory Ferraro  
Novartis Pharmaceuticals Corporation  
One Health Plaza  
East Hanover, NJ 07936-1080

Witnessed by:  
  
Signature  
  
Signature  
  
Printed name  
  
Printed name

Witnessed by:  
  
Signature  
  
Signature  
  
Printed name  
  
Printed name



**Power of Attorney**  
**(To Novartis IP colleagues based in US, UK, IT, DE, SG, CN)**

By this Power of Attorney, effective 01 January 2014, Novartis AG, a company incorporated under the laws of Switzerland and having its principal place of business at Lichtstrasse 35, 4056 Basel, Switzerland (“the Company”), hereby grants to the Novartis Group Companies listed below (“the Corporate Signatories”):

- a) the revocable authority to sign documents on behalf of the Company in connection with filing, prosecution, maintenance, and administration of any intellectual property right for copyright, design, domain name, patent, supplementary protection certificate (SPC) and trademark registration or any application therefore standing in the name of the Company (“IP”);
- b) the revocable authority to sign documents on behalf of the Company in connection with litigation relating to defense of IP before a governmental authority; and
- c) the revocable authority to sign Confirmatory Assignments on behalf of the Company. “Confirmatory Assignments” are agreements between the Company and a third party or a Novartis Group entity that do not create new rights or obligations for the Company, such rights having been created by an underlying agreement (e.g. acquisition/divestment agreement, research funding/collaboration agreement, and the like) and whereby the Confirmatory Assignment merely executes the transfer of IP as agreed in such underlying agreement;

and for no other purposes.

This Power of Attorney **excludes the power to conclude contracts, other than Confirmatory Assignments, or to enter into settlements on behalf of the Company.** The terms “contracts” and “settlements” include license agreements, acquisition/divestment agreements, assignments, prior right agreements and/or letters of consent.

This Power of Attorney includes the power to appoint external agents within the scope of this Power of Attorney.

To be legally binding upon the Company, all relevant documents require the signature of two employees of the Corporate Signatory as set out below (“Personal Signatories”) authorized to sign for the respective Corporate Signatory, except where a single Personal Signatory is permitted according to the Novartis internal “Intellectual Property Signature Guidelines” .



**Corporate Signatories**

**Personal Signatories**

---

Alcon Laboratories, Inc.

Catherine D. Murray  
Christianne K. Garrow  
Denise C. Vivar  
Mary Lozano  
Stephanie J. Boyle  
Sheldon R. Pontaoe

Alcon Research, Ltd.

Barbara McKenzie  
Barry L. Copeland  
Candace Sanders  
Christine Bohmann  
Christine Santelli  
Darden Weiss  
Darien L. Reddick  
Deborah Weinschenk  
Deena Nutt  
Gergely T. Zimanyi  
Glenda Wolfe  
Gregg C. Brown  
Jason J. Derry  
Jian Zhou  
Jonathan E. Prejean  
Keiko Ichiye  
Kelly Bryant  
Kenneth D. Bassinger  
Mark E. Flanigan  
Martha J. Martin  
Michael Rein  
Patrick M. Ryan  
Robert Ambrose  
Russell E. Henrichs  
Matthew A. Hayenga  
Scott A. Chapple  
Sheldon R. Pontaoe  
Shelley Rose  
Sheng Hu  
Sue Stockton  
Tracy Humphreys  
W. David Lee

Novartis Healthcare Private Limited

Atul Bade  
Ashish Jogi

Novartis Vaccines and Diagnostics GmbH

Graham Wilkinson

**Corporate Signatories****Personal Signatories**

Novartis Vaccines and Diagnostics, S.r.l.

Antoine Courgeon  
Stephen Evans  
Ilaria Ferrarini  
Marta Palla

Sandoz International GmbH

Andrea Felbermeir  
Britta Chamberlain  
Manuela Hillewaert  
Meike Urban  
Susanne Groeschel-Jofer  
Tanya Fickenscher-Leonard

Novartis Animal Health US, Inc.

Delisa Daniels  
Todd Sladek  
Jennifer Story  
Clint Vranian  
Latonya Raston

Novartis Consumer Health, Inc.

Alison Kessler  
Beth Nussbaum  
Diane Furman  
Greg Tole  
Mary Cheli  
Mary Leheny  
Nazuki Hughes  
Maria Stachura

Novartis Vaccines and Diagnostics, Inc.

Alishia Collins Rowe-Babb  
Amy Hessler  
Amy Olinger  
Beth O'Brien  
Christy Snyder  
David Carpenter  
Helen Lee  
Joanna Burns  
John Ward  
Juerg Baenziger  
Kenneth M. Goldman  
Lisa Alexander  
Lisa Nash  
Mei Hong  
Michael G. Smith  
Marco Riensche  
Nick Finnie  
Norma Gallina  
Regina Bautista



**Corporate Signatories**

**Personal Signatories**

---

Novartis Corporation

Betty Ryberg

Novartis Institutes for BioMedical Research,  
Inc.

Alvin Fitzgerald  
Arlene Musser  
Frank Wu  
Jasbir Sagoo  
Jean Silveri  
Jill Clarke  
John B. Alexander  
John Prince  
Joshua Roth  
Karen Lacourse  
Laura Madden  
Leslie Gould  
Matthew Beaudet  
Mei Benni  
Melissa Ponziano  
Paul Paglierani  
Qian Zhang (Andy) [张谦]  
Scott Brown  
Scott Reid  
Sophie Binet Cross  
Susan Dillon

Novartis Institute for Functional Genomics,  
Inc.

Chihang Amy Smith  
Daniel E. Raymond  
Emily Tongco-Wu  
Kerri Pollard Schray  
Lisa Watts  
Susan Sesnovich  
Timothy L. Smith

CIBA VISION Vertriebs GmbH

Frank Kaul  
Frank Hauerken  
Jan-Thore Föhrenbach

---

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.